GRAIL (GRAL) Jefferies Global Healthcare Conference 2025 summary

Strategic Vision, Market Opportunity, and Industry Context

• Focused on early cancer detection with Galleri, a multi-cancer early detection (MCED) test designed for population-scale screening.

• Cancer is the second leading cause of death globally, with 10 million deaths and 19 million new cases annually.

• About 70% of cancer deaths result from cancers without recommended screening, and 86% of cancers are not found through current screening methods.

• Total addressable market exceeds 100 million in the U.S., with expansion potential in the U.K., EU, and Japan, and over 300 million eligible adults globally.

• Partnerships with Quest Diagnostics, athenahealth, and major insurers streamline test ordering and access.

Clinical Evidence, Product Innovation, and Performance

• Galleri is a clinically validated, commercially available MCED blood test with over 640,000 tests run and more than 325,000 commercial tests sold through March 2025.

• PATHFINDER, NHS-Galleri, and CCGA studies show high specificity (99.5%) and positive predictive value (43-44%), with no serious safety concerns.

• About half of Galleri-detected cancers are early stage, and most have no routine screening.

• Consistent performance and localization accuracy across multiple study types.

• Longitudinal NHS-Galleri trial results expected mid-2026 to demonstrate clinical utility at scale.

Commercial Momentum, Partnerships, and Financial Outlook

• FY 2024 U.S. Galleri revenue grew 45% year-over-year to $109M, with Q1 2025 revenue at $32M, up 19% year-over-year.

• Cash balance of $678M as of March 31, 2025, provides runway into 2028; projected 2025 cash burn capped at $320M.

• Projected U.S. Galleri sales growth for 2025 is 20-30%, with repeat testing volume exceeding 20% in early 2025.

• Strong partnerships with organizations such as MassMutual, John Hancock, NVIDIA, and Southern Company support adoption.

• Automation and infrastructure investments support scalability and cost reduction as volume grows.